万维书刊网微信二维码

扫微信,关注编辑QQ!

您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生1>>妇产科学
您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生2>>生殖生物学

FERTILITY AND STERILITY《生育与不孕》 (官网投稿)

简介
  • 期刊简称FERTIL STERIL
  • 参考译名《生育与不孕》
  • 核心类别 高质量科技期刊(T1), SCIE(2024版), 目次收录(维普),外文期刊,
  • IF影响因子
  • 自引率8.70%
  • 主要研究方向医学-OBSTETRICS & GYNECOLOGY 妇产科学;REPRODUCTIVE BIOLOGY 生殖生物学

主要研究方向:

等待设置主要研究方向
医学-OBSTETRICS & GYNECOLOGY 妇产科学;REPRODUCTIVE BIOLOGY 生殖生物学

FERTILITY AND STERILITY《生育与不孕》(月刊). Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologis...[显示全部]
征稿信息

万维提示:

1、投稿方式:在线投稿。

2、期刊网址:

https://www.journals.elsevier.com/fertility-and-sterility

3、投稿网址:

https://www.editorialmanager.com/FNS/default.aspx

4、官网邮箱:fertstert@asrm.org

5、官网电话:205-978-5000 x139

6、期刊刊期:月刊,一年出版12期。

2021716日星期五

                                 

 

投稿须知【官网信息】

 

Guide for Authors

Only those manuscripts which are original, have not been published elsewhere, and are not currently being considered for inclusion in another publication will be considered for publication in Fertility and Sterility®. Authors are advised to keep a copy of all manuscripts submitted.

All manuscripts will be evaluated by peer reviewers who will remain anonymous. Selection of the peer reviewers is at the sole discretion of the Fertility and Sterility® editors. The editors and reviewers do not disclose any information about a manuscript or its review. If revisions are required, authors are asked to return the revised manuscripts within 40 days for the first revision, and within 30 days for any subsequent revisions. Please notify the editorial office if additional time is needed or if you choose not to submit a revision.

Authors are strongly encouraged to limit article length to 3,500 words for effective and efficient communication. If substantial merit would be gained from increasing the number of words in an article, longer submissions may be considered for publication. A combined maximum of 4 total figures and tables is allowed for the print version. Article length does not include the running title, title page, capsule, abstract, or references.

If you wish, you may include expanded discussion of the materials and methods section, or additional figures or tables, as supplemental material. This supplemental material will be published in the online version only, and will be referenced in the print version. Please indicate in your cover letter which sections are intended to be supplemental material. Title any supplemental figures or tables as “Supplemental figure 1,” and so on.

REQUIREMENTS FOR SPECIFIC ARTICLE TYPES

Reviews

Reviews are generally by invitation only, but unsolicited systematic reviews and meta-analyses will be considered if they are in the style of the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA), details of which can be found at http://www.prisma-statement.org. Systematic reviews/meta-analyses should be formatted according to the “Preparation of Manuscript.”

Video Articles

Video submissions are peer reviewed, citable and indexed as publications in PubMed. The video article format allows you to provide a video demonstration of both the data and technique of your study.

Authors should submit a cover letter, title page, structured abstract, and reference list (submit the title page, abstract, and references as the “Manuscript”) through the Editorial Manager website for this journal (https://www.editorialmanager.com/FNS/default.aspx). The video itself should be submitted to a Dropbox file. The corresponding author will receive an invitation to the Dropbox after the manuscript has been submitted through Editorial Manager.

Video articles should provide a significant contribution to the medical literature. They should include original data or provide a review of a subject. The visual demonstration of the topic is a key component and the video should demonstrate information beyond what would be in text alone. Videos should NOT be a series of text-only slides.

Length: Videos should have a maximum length of 8 minutes.

Videos should have an audio narration track. Silent videos will not be likely to be accepted.

Music should be used with careful consideration. When utilized creatively, music can enhance some videos. If music is used, the author must obtain permission from the copyright holder or documentation that the music is royalty-free.

The start of the video should include the title of the video and the author's name and institution.

Commercial-type messages should not be used.

File formats: WMV, AVI, MOV, or MP4 are accepted.

Aspect ratio: We prefer videos to be in 16:9 format because we use 16:9 aspect ratio players. If you are uploading a non-16:9 file, it will be processed and displayed correctly as well, with pillar boxes or letter boxes provided by the player. If you want to fit the player perfectly, encode at these resolutions:

    1080p: 1920×1080

    720p: 1280×720

Resolution: Please submit your video files in HD 1080P. We accept 72 P but prefer higher resolution. We do not accept video files with standard definition.

Suggested bitrates for uploads:

    Format 1080P: video bitrate 8,000 kbps; Mono Audio bitrate 128 kbps; stereo audio bitrate 384 kbps

    Format 720P: video bitrate 5,000 kbps; Mono Audio bitrate 128 kbps; stereo audio bitrate 384 kbps

Any patient identification must be removed or masked.

Monographs, Supplements, and Compilations

Supplements are paginated like a regular journal issue and consist of peer-reviewed original research. The cover is clearly identified with the volume and number, and the articles can be cited. Monographs are not peer-reviewed, are not identified as part of the regular journal, are not paginated, and cannot be cited. Compilations are previously published journal articles with an index indicating where each article was published. All requests for publication of monographs, supplements, or compilations should be referred to the Publications Committee.

Letters to the Editor

Fertility and Sterility has phased out “Letters to the Editor” in favor of the real-time, interactive Fertility and Sterility Dialog. For instructions on how to post your comments regarding articles in our journal, please see https://www.fertstertdialog.com/pages/fertstert-about.

CONTACT INFORMATION

All correspondence regarding submitted manuscripts will be handled via e-mail through EM. Send all other correspondence to:

Fertility and Sterility®

American Society for Reproductive Medicine (ASRM)

1209 Montgomery Highway

Birmingham, AL 35216

P: 205-978-5000 x139

F: 205-978-5005

E: fertstert@asrm.org

Ethics in Publishing

Authors

Conditions of Authorship.

Authors should have made significant conceptual, intellectual, experimental, and analytical contributions to the research, as well as having participated in writing and revising the manuscript.

Each author should have participated sufficiently in the work to take public responsibility for its content.

Honorary authorship (i.e., not adhering to the conditions of authorship and, none-the-less, being granted authorship) is not permitted.

All authors must sign the Statement of Authorship (typed or printed name is not acceptable) and include the form on initial submission.

Responsibilities of Authors.

Authors must describe the research in sufficient detail such that others could repeat it.

Written, informed consent under protocols approved by an institutional or local review board or approved animal protocols are essential if the research involves human or animal subjects, respectively. This information should be stated in the manuscript and the protocol number or exempt status of approved protocols should be stated in the manuscript at the time of submission for review.

Authors of clinical trials are required to prospectively register their trial with one of the ICMJE-recognized trial registries (5).

Selective reporting of data is inappropriate, especially if unreported data are in disagreement with the findings of the selectively reported data. In accordance with the ICJME, the ASRM supports publication of negative studies.

Authors should cite publications in the literature that are relevant to the uniqueness of the research and should including publications by others, as well as of their own research group.

Previous publication of a preliminary report on the data is permissible, if this is stated clearly in a footnote in the manuscript.

Scientific Misconduct. Definition. The DHHS Office of Research Integrity defines plagiarism, fabrication, and falsification.

The ASRM accepts these definitions and considers them to constitute scientific misconduct. Additional unethical behavior that comprises scientific misconduct includes: submission of results from animal or clinical research that was conducted without appropriate approval and written, informed consent; duplicate publication; and honorary authorship. Research misconduct occurs when results are falsified, fabricated or plagiarized. The actions are willful or intentional, although the actual definition of misconduct varies somewhat by country. This can occur at various times during the process of proposing, performing or reviewing research.

Differences of opinion or honest errors do not constitute misconduct.

Fabrication: Data, results or recording or reporting information that does not exist

Falsification: Changing research materials, equipment or processes; omission of data or results. As a consequence, the research is not accurately represented in the research records.

Plagiarism: Using another person’s words, ideas, results, and processes without giving credit to them. Plagiarism includes the theft of intellectual property, ideas or methods such as the use of information gained by personal communication, or during a grant or manuscript review. Plagiarism also includes the direct textual copying of another person’s work. Direct copying of 100-250 words constitutes plagiarism. Authorship disputes are not included in this definition. Citation plagiarism is the failure to credit others with prior discoveries and is extremely common. Self-plagiarism can include multiple publications of the same manuscript in different journals or books.

Submission without animal or human subjects oversight approvals. Any manuscript submitted without proof of animal or human subjects approval by institutional or local IRBs will not be reviewed and will be returned to the authors.

Duplicate publication. Duplicate publication can take several forms:

Duplicate Publication with other journals. On occasion ASRM journals may decide to publish an article simultaneously with another journal, e.g., with consensus statements from consensus conferences. Such intention on the part of the Editor-In-Chief should be discussed with the Publications Committee immediately after the two journals have had discussion so that Publications Committee members can assess the appropriateness of such joint publications and approve or disapprove.

Publication of identical data. The ASRM considers that disclosure, citing the original publication, and obtaining permission are essential. Without all of these, publication of identical data is inappropriate and not permissible.

Salami” publications. Dividing data, analysis, and presentation into “minimally publishable units” is a slippery slope, and can be used to extend one data set over several manuscripts. While this may be acceptable for clarity of presentation and focus on specific outcomes in different manuscripts, a motivation may also be to increase the publication list in an author’s CV. The latter is unethical and unacceptable. Therefore, please acknowledge in your cover letter any similar publications or submitted manuscripts

Partial publication. Partial presentation of data in another medium (e.g., on a website) does not necessarily preclude publication in Fertility and Sterility, but acknowledgment of the previous presentation is required, along with identification of the source (e.g., the URL of the website). Content cannot be copied verbatim from the previous presentation, as that would constitute self-plagiarism, but must be rewritten to comply with journal standards.

Investigation of scientific misconduct. All cases of suspected misconduct will be investigated initially by the Editor-In-Chief and the Publications Committee of the American Society for Reproductive Medicine to determine if the evidence of misconduct is sufficient to proceed with a formal inquiry. If so, the author will be notified in writing of the allegations, and will be asked to provide information useful to the investigation, including access to all original data, notes, and copies of prior publications. The author’s institution may be contacted, as well. Processing and publication of the manuscript will be delayed while the matter is resolved. Confidentiality will be maintained and care taken to protect the rights and reputations of all concerned. The final decision on disposition of the paper and any sanctions against the author will be made by the Editor-In-Chief in concert with the Publications Committee.

Potential sanctions include, but may not be limited to: rejection of a manuscript in process; a letter of reprimand to the author, copied to the author’s institution; and correction or retraction of the manuscript, including a statement in the print issue detailing the nature of the misconduct.

Reviewers. Reviewers have the responsibility to objectively and fairly review the manuscript. If there is a conflict of interest or if the reviewer does not have the requisite expertise, then the manuscript should be immediately returned to the Editor for reassignment. Strict confidentiality is required during the review process. If any portion of a manuscript is shared before the review is completed and before acceptance and publication, written consent of the authors is required.

Conflict of Interest

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If there are no conflicts of interest then please state this: 'Conflicts of interest: none'. See also https://www.elsevier.com/conflictsofinterest. Further information and an example of a Conflict of Interest form can be found at: http://icmje.org/disclosure-of-interest/.

Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.

Use of inclusive language

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

Authorship

To meet the criteria for authorship, in accordance with the Fertility and Sterility instructions for authors, all authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, AND (2) drafting the article or revising it critically for important intellectual content, AND (3) final approval of the version to be submitted, AND (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Changes to authorship

Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

Reporting clinical trials

Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The CONSORT checklist and template flow diagram are available online.

Registration of Clinical Trials (ICMJE)

Registration in a public trials registry is a condition for publication of clinical trials in this journal in accordance with International Committee of Medical Journal Editors (ICMJE, http://www.icmje.org) recommendations. Trials must be registered at or before the onset of patient enrollment. The clinical trial registration number should be included at the end of the abstract of the article. A clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioral treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

The ICMJE accepts registration in the following registries:

http://www.anzctr.org.au

http://www.clinicaltrials.gov

http://www.ISRCTN.org

http://www.umin.ac.jp/ctr/index/htm

http://www.trialregister.nl

https://eudract.ema.europa.eu/ (new registrations after June 20, 2011)

In addition to the above registries, starting in June 2007 the ICMJE will also accept registration in any of the primary registries that participate in the WHO International Clinical Trials Portal (see http://www.who.int/ictrp/network/primary/en/index.html). Because it is critical that trial registries are independent of for-profit interests, the ICMJE policy requires registration in a WHO primary registry rather than solely in an associate registry, since for-profit entities manage some associate registries. Trial registration with missing or uninformative fields for the minimum data elements is inadequate even if the registration is in an acceptable registry.

Copyright

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete a 'License Agreement' (more information). Permitted third party reuse of gold open access articles is determined by the author's choice of user license.

Author rights

As an author you (or your employer or institution) have certain rights to reuse your work. More information.

Role of the Funding Source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated. Please see https://www.elsevier.com/funding.

Open access

Please visit our Open Access page for more information.

Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's Author Services.

Submission

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Submit Your Article

Please submit your article via https://www.editorialmanager.com/FNS/default.aspx?pg=mainpage.html.

……

更多详情:

https://www.elsevier.com/journals/fertility-and-sterility/0015-0282/guide-for-authors


  • 万维QQ投稿交流群    招募志愿者

    版权所有 Copyright@2009-2015豫ICP证合字09037080号

     纯自助论文投稿平台    E-mail:eshukan@163.com


投稿问答最小化  关闭